OPX Biotechnologies (OPXBIO) recently announced the close of its Series C financing, totaling $36.5 million. OPXBIO uses its Efficiency Directed Genome Engineering (EDGE) platform to genetically modify microbes to generate...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)